Background
==========

Cervical cancer (CC) is the second leading cause of death among women worldwide \[[@b1-medscimonit-24-8383]\]. Although there has been notable progress in CC treatment, including surgical techniques, chemotherapy, and radiotherapy, in the past 2 decades, there are still some early cases that have invasion and metastasis, which directly affects the prognosis of CC \[[@b2-medscimonit-24-8383]\]. At present, the underlying molecular mechanism of CC pathogenesis is still unclear. Thus, to improve the survival of CC patients, it is important to find new potential prognostic biomarkers and therapeutic targets.

The coiled-coil domain-containing 34 (CCDC34), also named NY-REN-41, includes 373 amino acids and locates in 11p14.1 chromosome. CCDC34 was initially found in a patient with hamartoma of the retinal pigment epithelium and retina \[[@b3-medscimonit-24-8383]\]. Recently, Gong et al. \[[@b4-medscimonit-24-8383]\] found that CCDC34 was overexpressed in bladder cancer and promoted its cell proliferation and migration. However, the expression level and prognostic value of CCDC34 in human cervical cancer remain largely unclear.

In this study, GEPIA and Oncomine cancer databases were mined to predict the CCDC34 differential expression level between a CC group and a normal group. Then, immunohistochemical staining was performed to detect the expression levels of CCDC34, VEGF, and microvessel density (MVD) in CC. Moreover, CCDC34 expression level in CC and its correlations with patients' clinicopathological characteristics and survival prognosis were investigated.

Material and Methods
====================

Bioinformatics mining
---------------------

GEPIA (*<http://gepia.cancer-pku.cn/>*) and Oncomine (*<https://www.oncomine.org/resource/login.html>*) cancer databases were mined to predict the CCDC34 differential expression level between a CC group and a normal group.

Patients and corresponding clinical characteristics
---------------------------------------------------

We retrospectively included 67 patients diagnosed with cervical cancer after radical surgery in our hospital from August 2009 to December 2011. Surgical staging was based on the FIGO system. All patients' clinicopathological factors are listed in [Table 1](#t1-medscimonit-24-8383){ref-type="table"}. This study was approved by the Ethics Committee of the Tumor Hospital of Ganzhou Review Board (No. 20140702). Informed consent was signed by each patient.

Immunohistochemistry and results evaluation
-------------------------------------------

Immunohistochemistry was performed to examine the expression levels of CCDC34 (ab122396, Abcam, Inc.), VEGF (ab2349, Abcam, Inc.) and CD31 (ab28364, Abcam, Inc.) according to the manufacturer's instructions. The working concentration of each antibody was at a dilution of 1: 100. Immunohistochemical scores were calculated based on a previously reported method \[[@b5-medscimonit-24-8383]\]: "+" score for ≥10% of tumor cells positive; "−" score when less than 10% of tumor cells or no visible staining was detected.

MVD counts
----------

MVD counts were calculated by vascular endothelial cells with CD31-positive staining. We used low-magnification (×40) microscopy to identify regions with the maximum number of CD31-positive-staining microvessels. Then, we used high magnification (×100) to count the number of microvessels. Each section was independently observed and calculated by 2 pathologists.

Statistical analysis
--------------------

SPSS 20.0 software was used to perform the statistical analysis. Data in GEPIA and Oncomine databases were analyzed by the independent-samples *t* test to compare the differential expression levels of CCDC34 mRNA between the cervical cancer group and the normal group. Pearson χ^2^ test or Fisher test was employed to evaluate the correlation between CCDC34 expression and clinicopathological factors. Kaplan-Meier univariate and Cox multivariate survival analyses were performed to assess the CCDC34 prognostic value in CC patients. A *P* value less than 0.05 was considered as a significantly statistical difference.

Results
=======

High expression of CCDC34 and its relationship with CC patients' clinicopathological factors
--------------------------------------------------------------------------------------------

Both GEPIA and Oncomine cancer databases mining results revealed that CCDC34 was more highly expressed in the CC group than that in the normal group (all *P*\<0.05, [Figure 1](#f1-medscimonit-24-8383){ref-type="fig"}). Then, immunohistochemistry was used in 67 cervical cancer and corresponding adjacent tissues to examine the clinicopathological and prognostic significance of CCDC34 in cervical cancer. The positive staining of CCDC34 was primarily located in the cytoplasm and membrane ([Figure 2A](#f2-medscimonit-24-8383){ref-type="fig"}). The CCDC34-positive staining rate was 71.6% (48/67) in cervical cancer tissues, while in adjacent non-cancerous tissues, only 14 of 67 (20.9%) corresponding paracarcinomatous showed CCDC34-positive staining ([Figure 2B](#f2-medscimonit-24-8383){ref-type="fig"}). A statistically significant difference was found between these 2 groups of tissues in the positive rate of CCDC34 (*P*\<0.001, [Figure 3](#f3-medscimonit-24-8383){ref-type="fig"}). The relationship between CCDC34 expression levels and CC patients' clinicopathological parameters are listed in [Table 1](#t1-medscimonit-24-8383){ref-type="table"}. High expression of CCDC34 was significantly associated with histological grade (*P*=0.022), lymph node metastasis (*P*=0.044), and FIGO stage (*P*=0.002).

Correlation between CCDC34 and VEGF expression in CC patients
-------------------------------------------------------------

VEGF-positive staining was mainly located in the cytoplasm ([Figure 2C](#f2-medscimonit-24-8383){ref-type="fig"}) and the VEGF-positive staining rate was 59.7% (40/67). The CCDC34-positive and VEGF-positive rate were both 55.2% (37/67), and the consistency of both CCDC34 and VEGF expression was 74.6% (50/67). Furthermore, Spearman's test revealed a strong relationship between CCDC34 and VEGF expression in CC tissues (*r*=0.563, *P*=0.000; [Table 2](#t2-medscimonit-24-8383){ref-type="table"}).

Association between CCDC34 and MVD in CC
----------------------------------------

As shown in [Figure 4](#f4-medscimonit-24-8383){ref-type="fig"}, CC patients with CCDC34-positive expression had much more MVD than those with CCDC34-negative expression (*P*=0.000).

Correlation between CCDC34 and CC patients' prognosis
-----------------------------------------------------

Based on TCGA database, patients with high expression of CCDC34 had worse OS than those with low expression of CCDC34 (*P*=0.015, [Figure 5A](#f5-medscimonit-24-8383){ref-type="fig"}). Compared to those with CCDC34-negative expression, CC patients with CCDC34-positive expression had shorter OS and DFS times (*P*=0.004, [Figure 5B](#f5-medscimonit-24-8383){ref-type="fig"} and *P*=0.005, [Figure 5C](#f5-medscimonit-24-8383){ref-type="fig"}, respectively).

CCDC34 can serve as a predictive parameter for the prognosis of CC patients
---------------------------------------------------------------------------

Kaplan-Meier univariate survival analysis showed that CCDC34 expression, recurrence, and FIGO stage had significant prognostic influence on OS and DFS ([Table 3](#t3-medscimonit-24-8383){ref-type="table"}). Cox multivariate survival analysis revealed that CCDC34 was an independent prognostic factor for OS (*P*=0.039) and DFS (*P*=0.040) ([Table 4](#t4-medscimonit-24-8383){ref-type="table"}).

Discussion
==========

The coiled-coil domain-containing (CCDC) proteins exhibit diverse functions related to their highly versatile folding motif \[[@b6-medscimonit-24-8383]\]. Previous studies have shown genetic or epigenetic alterations in several CCDC genes in human cancers, including CCDC34 in bladder cancer \[[@b4-medscimonit-24-8383]\], colorectal cancer \[[@b7-medscimonit-24-8383]\], pancreatic adenocarcinoma \[[@b8-medscimonit-24-8383]\], and esophageal squamous cell carcinoma \[[@b9-medscimonit-24-8383]\]. However, to date, there has been no study focusing on the relationship between CCDC34 and cervical cancer. In this study, our results proved that CCDC34 was overexpressed in cervical cancer compared to corresponding adjacent normal tissues. Further findings demonstrated that high expression of CCDC34 was significantly associated with histological grade, lymph node metastasis, and FIGO stage. These data suggest a key role of CCDC34 in progression and development of cervical cancer.

Accumulating evidence demonstrates that high expression of VEGF is closely related to aggressive behavior and worse prognosis of cancer \[[@b10-medscimonit-24-8383]\]. In addition, high VEGF expression levels and MVD are strongly associated with unfavorable prognosis of CC patients \[[@b11-medscimonit-24-8383]--[@b14-medscimonit-24-8383]\]. In the present study, we similarly observed a significant positive correlation between CCDC34 and VEGF expression in CC tissues. Compared to those with CCDC34-negative expression, patients with CCDC34-positive expression had much more MVD. These findings suggest that CCDC34 participates in tumor angiogenesis of CC, possibly in coordination with VEGF. Similarly, Gong et al. \[[@b4-medscimonit-24-8383]\] demonstrated that knockdown of CCDC34 retards bladder cancer proliferation and migration by downregulating the PI3K/AKT pathway. The AKT pathway has a pivotal regulatory role in multiple cellular survival pathways, primarily in tumorigenesis and angiogenesis, by regulating VEGF expression \[[@b15-medscimonit-24-8383]\]. This suggests that CCDC34 facilitates VEGF expression by regulating the PI3K/AKT signaling pathway. Hu et al. \[[@b9-medscimonit-24-8383]\] found that CCDC34 was highly expressed in ESCC, and high expression of CCDC34 was associated with poor prognosis of ESCC patients, the potential mechanism of which is closely related to the angiogenesis of ESCC; these results are consistent with our own. More in-depth studies are required to elucidate the role of CCDC34 in CC angiogenesis.

We also explored the relationship between CCDC34 expression and prognosis of CC patients. Kaplan-Meier univariate survival analysis demonstrated that patients with CCDC34-positive expression had shorter OS and DFS than those with CCDC34-negative expression. In addition*,* Cox multivariate survival analysis revealed that CCDC34 was an independent unfavorable predictor for OS and DFS of CC patients. The bioinformatics mining results were consistent with our experimental data.

The present study has certain limitations. First, small cervical cancer tissue samples were collected retrospectively, which might to some extent lead to biased statistical results. Second, only immunohistochemical staining, a semi-quantitative method, was used in our validation experiment, and some other quantitative methods like Western blot or qRT-PCR analysis are needed. Third, the exact biological function of CCDC34 in cervical cancer and its detailed molecular regulation mechanisms were not assessed in this study. We plan to address these deficiencies in our future experiments.

Conclusions
===========

Our results proved that high expression of CCDC34 was closely associated with CC angiogenesis and is as an independent poor prognostic parameter in CC.
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![Bioinformatics mining results. (**A**) GEPIA mining results (Based on TCGA data), \* *P*\<0.05. (**B, C**) Oncomine mining results based on GEO data, and the GSE number of each dataset was GSE7410 and GSE6791, respectively.](medscimonit-24-8383-g001){#f1-medscimonit-24-8383}

![Immunochemical staining of CCDC34 and VEGF. High (**A**) and low (**B**) expression of CCDC34 protein in cervical cancer tissues. (**C**) Expression of VEGF protein in cervical cancer tissues. Bar=50 um.](medscimonit-24-8383-g002){#f2-medscimonit-24-8383}

![IHC scores of CCDC34 and VEGF expressions in cervical cancer and matched paracarcinomatous tissues.](medscimonit-24-8383-g003){#f3-medscimonit-24-8383}

![Intratumoral microvessel density (MVD) in relation to CCDC34 protein immunoreactivity. Cervical cancer patients with CCDC34-positive expression showed significantly higher intratumoral MVD than those with CCDC34-negative expression.](medscimonit-24-8383-g004){#f4-medscimonit-24-8383}

![Kaplan-Meier analysis of overall survival (OS) and disease-free survival (DFS) curves of patients with cervical cancer based on CCDC34 expression levels. (**A**) OS curve of patients with cervical cancer based on TCGA database. (**B**) OS curve of patients with cervical cancer based on CCDC34 expression. (**C**). DFS curve of patients with cervical cancer based on CCDC34 expression.](medscimonit-24-8383-g005){#f5-medscimonit-24-8383}

###### 

CCDC34 expression status in relation to selected clinicopathologic features in 67 cervical cancer patients.

  Characteristics               n    CCDC34   χ^2^   *P*     
  ----------------------------- ---- -------- ------ ------- -------
                                     19       48             
  Age                                                        
   \<40                         32   10       22     0.252   0.616
   ≥40                          35   9        26             
  Tumor length (cm)                                          
   \<4                          30   7        23     0.675   0.411
   ≥4                           37   12       25             
  Histology                                                  
   SCC                          52   14       38     0.026   0.873
   Adenocarcinoma               15   5        10             
  Histological grade                                         
   G1                           31   13       18     5.235   0.022
   G2--3                        36   6        30             
  Cervical infiltration depth                                
   \<2/3                        24   9        15     1.538   0.215
   ≥2/3                         43   10       33             
  Lymphovascular permeation                                  
   Yes                          29   7        22     0.448   0.503
   No                           38   12       26             
  Lymph node metastasis                                      
   Yes                          23   3        20     4.043   0.044
   No                           44   16       28             
  Recurrence                                                 
   Yes                          26   5        21     1.742   0.187
   No                           41   14       27             
  FIGO stage                                                 
   I                            33   15       18     9.356   0.002
   II                           34   4        30             

###### 

Correlation between CCDC34 and VEGF expression (cases).

  Staining indicator   CCDC34   *r*   *P* value   
  -------------------- -------- ----- ----------- -------
  VEGF                                            
  \+                   37       3     0.563       0.000
  −                    11       16                

###### 

Univariate analysis of factors associated with OS and DFS.

  Characteristics               DFS              OS                       
  ----------------------------- ---------------- ------- ---------------- -------
  CCDC34                                                                  
   Negative                     63.443--69.113           63.800--69.066   
   Positive                     33.618--46.424   0.005   38.468--49.075   0.004
  Age                                                                     
   \<40                         40.246--57.905           44.853--59.670   
   ≥40                          42.217--57.184   0.051   45.369--58.231   0.638
  Tumor length(cm)                                                        
   \<4                          38.817--55.453           42.416--56.706   
   ≥4                           43.864--59.824   0.606   47.735--61.180   0.575
  Histology                                                               
   SCC                          42.973--55.765           46.528--57.265   
   Adenocarcinoma               35.342--58.614   0.320   39.611--59.900   0.293
  Histological grade                                                      
   G1                           43.619--58.282           46.997--59.257   
   G2--3                        40.429--57.501   0.835   44.663--59.294   0.801
  Cervical infiltration depth                                             
   \<2/3                        47.721--62.705           49.522--62.853   
   ≥2/3                         38.829--54.533   0.118   43.487--56.755   0.128
  Lymphovascular permeation                                               
   Yes                          35.604--53.187           39.757--55.143   
   No                           46.073--61.170   0.196   49.869--62.297   0.198
  Lymph node metastasis                                                   
   Yes                          31.353--51.163           36.717--53.496   
   No                           47.855--61.621   0.050   50.653--62.486   0.047
  Recurrence                                                              
   Yes                          30.894--50.851           36.434--53.160   
   No                           49.095--62.285   0.045   51.663--63.093   0.043
  FIGO stage                                                              
   I                            30.681--47.422           36.617--50.266   
   II                           53.245--64.636   0.030   54.065--64.858   0.046

###### 

Multivariate analysis of factors associated with OS and DFS.

  Factors                                          DFS     OS                                              
  ------------------------------------------------ ------- --------------- ------- ------- --------------- -------
  CCDC34 (negative *vs.* positive)                 4.798   1.072--21.478   0.040   5.617   1.094--28.838   0.039
  Age (\<40 *vs.* ≥40)                             0.416   0.162--1.064    0.067   0.451   0.176--1.153    0.096
  Tumor length (\<4 *vs.* ≥4 cm)                   0.726   0.262--2.006    0.536   0.746   0.276--2.016    0.563
  Histology (SCC *vs.* adenocarcinoma)             0.440   0.162--1.200    0.109   0.448   0.167--1.199    0.110
  Histological grade (G1 *vs.* G2+G3)              0.613   0.260--1.443    0.262   0.661   0.282--1.549    0.340
  Cervical infiltration depth (\<2/3 *vs.* ≥2/3)   3.116   0.903--10.760   0.072   2.922   0.856--9.979    0.087
  lymphovascular permeation (no *vs.* yes)         1.745   0.760--4.003    0.189   1.593   0.702--3.616    0.265
  Lymph node metastasis (no *vs.* yes)             1.045   0.419--2.609    0.925   1.041   0.418--2.592    0.932
  Recurrence (no *vs.* yes)                        3.879   1.343--11.204   0.012   3.807   1.343--10.795   0.012
  FIGO stage (I *vs.* II)                          1.865   0.710--4.898    0.206   1.688   0.629--4.529    0.299
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